{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:05:47Z","timestamp":1784570747191,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023867","name":"Swedish Stroke Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023867","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Avtal om L\u00e4karutbildning och Forskning agreement"},{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Reversal treatment is used to counterbalance effects of oral anticoagulation in intracranial hemorrhages. Despite effects on reducing hematoma expansion, the impact on mortality remains uncertain. Our aim was to assess the effects of reversal treatment on mortality in various forms of oral anticoagulant-associated intracranial hemorrhage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic searches were performed in the electronic databases of PubMed, Embase, Scopus, and Web of Science from database inception to March 2025. We included studies that compared mortality between patients receiving reversal treatment vs. non-reversal in oral-anticoagulant-associated intracranial hemorrhages. Only studies with appropriate statistical controlling for significant confounding variables were included. Data extraction and synthesis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Data were summarized and pooled effect estimates were presented. Outcome was mortality, and primarily with a follow-up limited to 3\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 8217 studies were screened; 8 were ultimately included, all observational, and including 8777 participants with documented reversal treatment. For the overall analysis, when all types of intracranial hemorrhage and all types of anticoagulants were included, reversal was associated with reduced mortality (RR 0.78 (95% CI 0.67\u20130.91);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). This association was also seen in the subgroup analysis of 8639 participants with nontraumatic intracerebral hemorrhage on any oral anticoagulant (RR 0.77 (95% CI 0.64\u20130.94);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009), but not among the 3059 participants with intracerebral hemorrhage treated with only direct oral anticoagulants (RR 0.91 (95% CI 0.80\u20131.03);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.15).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence for reduced mortality following anticoagulant reversal in intracranial hemorrhage is limited and primarily derived from observational studies. Although pooled data suggest a potential treatment benefit across various types of intracranial hemorrhages and anticoagulants, most hemorrhage subtypes remain insufficiently studied. Going forward, there is a critical need for randomized clinical trials and additional well-controlled observational studies to determine which patients truly benefit from reversal treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12028-026-02588-y","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:54:33Z","timestamp":1784570073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect on Mortality of Anticoagulant Reversal in Acute Intracranial Hemorrhage: A Systematic Review and Meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2392-5341","authenticated-orcid":false,"given":"Mattias","family":"Tallroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"\u00d6stlundh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"B\u00fcki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"von Euler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob O.","family":"Str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"4","key":"2588_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10072-019-3726-x","volume":"40","author":"R Pan","year":"2019","unstructured":"Pan R, Cheng J, Lai K, Huang Q, Wu H, Tang Y. Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis. Neurol Sci. 2019;40(4):813\u201327.","journal-title":"Neurol Sci"},{"issue":"19","key":"2588_CR2","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","volume":"390","author":"SJ Connolly","year":"2024","unstructured":"Connolly SJ, Sharma M, Cohen AT, et al. Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage. N Engl J Med. 2024;390(19):1745\u201355.","journal-title":"N Engl J Med"},{"issue":"7","key":"2588_CR3","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","volume":"53","author":"SM Greenberg","year":"2022","unstructured":"Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2022;53(7):e282-361.","journal-title":"Stroke"},{"key":"2588_CR4","unstructured":"Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication|FDA. Accessed May 14 2026]. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/update-safety-andexxa-astrazeneca-fda-safety-communication"},{"issue":"5","key":"2588_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack","year":"2017","unstructured":"Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431\u201341.","journal-title":"N Engl J Med"},{"issue":"12","key":"2588_CR6","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.3390\/jcm11123399","volume":"11","author":"S Rauch","year":"2022","unstructured":"Rauch S, M\u00fcller H-P, Dreyhaupt J, Ludolph AC, Kassubek J, Althaus K. Andexanet alfa for reversal of factor Xa inhibitors in intracranial hemorrhage: observational cohort study. J Clin Med. 2022;11(12):3399.","journal-title":"J Clin Med"},{"issue":"2","key":"2588_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54916","volume":"7","author":"B Ip","year":"2024","unstructured":"Ip B, Pan S, Yuan Z, et al. Prothrombin complex concentrate vs conservative management in ICH associated with direct oral anticoagulants. JAMA Netw Open. 2024;7(2):e2354916.","journal-title":"JAMA Netw Open"},{"issue":"20","key":"2588_CR8","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa0707534","volume":"358","author":"SA Mayer","year":"2008","unstructured":"Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127\u201337.","journal-title":"N Engl J Med"},{"issue":"24","key":"2588_CR9","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","volume":"77","author":"A G\u00f3mez-Outes","year":"2021","unstructured":"G\u00f3mez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol. 2021;77(24):2987\u20133001.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2588_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.40145","volume":"5","author":"R Chaudhary","year":"2022","unstructured":"Chaudhary R, Singh A, Chaudhary R, et al. Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage. JAMA Netw Open. 2022;5(11):e2240145.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2588_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1177\/0018578720946754","volume":"56","author":"EJ Owen","year":"2021","unstructured":"Owen EJ, Gibson GA, Human T, Wolfe R. Thromboembolic complications after receipt of prothrombin complex concentrate. Hosp Pharm. 2021;56(6):709\u201313.","journal-title":"Hosp Pharm"},{"key":"2588_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-090357","volume":"15","author":"M Tallroth","year":"2025","unstructured":"Tallroth M, \u00d6stlundh L, B\u00fcki A, Cao Y, von Euler M, Str\u00f6m JO. Reversal treatment and clinical outcomes in acute intracranial haemorrhage associated with oral anticoagulant use: protocol of a planned systematic review and meta-analysis. BMJ Open. 2025;15:e090357.","journal-title":"BMJ Open"},{"key":"2588_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2588_CR14","unstructured":"Ottawa Hospital Research Institute. Accessed May 29, 2025. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"1","key":"2588_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ana.24416","volume":"78","author":"AR Parry-Jones","year":"2015","unstructured":"Parry-Jones AR, Di Napoli M, Goldstein JN, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol. 2015;78(1):54\u201362.","journal-title":"Ann Neurol"},{"key":"2588_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jss.2020.12.004","volume":"260","author":"SG Lumas","year":"2021","unstructured":"Lumas SG, Hsiang W, Becher RD, Maung AA, Davis KA, Schuster KM. Choosing the best approach to warfarin reversal after traumatic intracranial hemorrhage. J Surg Res. 2021;260:369\u201376.","journal-title":"J Surg Res"},{"key":"2588_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00760","volume":"11","author":"T Apostolaki-Hansson","year":"2020","unstructured":"Apostolaki-Hansson T, Ullberg T, Pihlsg\u00e5rd M, Norrving B, Petersson J. Reversal treatment in oral anticoagulant-related intracerebral hemorrhage\u2014an observational study based on the Swedish Stroke Register. Front Neurol. 2020;11:760.","journal-title":"Front Neurol"},{"issue":"1","key":"2588_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.","journal-title":"BMC Med Res Methodol"},{"issue":"19","key":"2588_CR19","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Yu KF. What\u2019s the relative risk?: a method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690.","journal-title":"JAMA"},{"issue":"4","key":"2588_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamaneurol.2024.0221","volume":"81","author":"KN Sheth","year":"2024","unstructured":"Sheth KN, Solomon N, Alhanti B, et al. Time to anticoagulation reversal and outcomes after intracerebral hemorrhage. JAMA Neurol. 2024;81(4):363\u201372.","journal-title":"JAMA Neurol"},{"issue":"7414","key":"2588_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"05","key":"2588_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.33588\/rn.7305.2020565","volume":"73","author":"P Amores Valenciano","year":"2021","unstructured":"Amores Valenciano P, Ruiz-Escribano Taravilla E, Romero S\u00e1nchez CM, et al. Mortalidad en pacientes con hemorragia intracerebral asociada a anticoagulaci\u00f3n oral. Eficacia de un protocolo de reversi\u00f3n y seguimiento cl\u00ednico (proyecto HIC-ACO). Rev Neurol. 2021;73(05):165.","journal-title":"Rev Neurol"},{"issue":"4","key":"2588_CR23","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2023.7.FOCUS23380","volume":"55","author":"D Botros","year":"2023","unstructured":"Botros D, Gautam D, Hamrick FA, et al. Impact of premorbid oral anticoagulant use on survival in patients with traumatic intracranial hemorrhage. Neurosurg Focus. 2023;55(4):E2.","journal-title":"Neurosurg Focus"},{"issue":"6","key":"2588_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1747-4949.2012.00926.x","volume":"10","author":"J Huhtakangas","year":"2015","unstructured":"Huhtakangas J, Tetri S, Juvela S, et al. Improved survival of patients with warfarin-associated intracerebral haemorrhage: a retrospective longitudinal population-based study. Int J Stroke. 2015;10(6):876\u201381.","journal-title":"Int J Stroke"},{"key":"2588_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejim.2016.05.019","volume":"33","author":"C Becattini","year":"2016","unstructured":"Becattini C, Franco L, Masotti L, et al. Clinical management and outcome of major bleeding in patients on treatment with vitamin K antagonists. Eur J Intern Med. 2016;33:47\u201354.","journal-title":"Eur J Intern Med"},{"issue":"11","key":"2588_CR26","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/hs1101.098523","volume":"32","author":"L Sjoblom","year":"2001","unstructured":"Sjoblom L, Hardemark H-G, Lindgren A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke. 2001;32(11):2567\u201374.","journal-title":"Stroke"},{"issue":"8","key":"2588_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/MBC.0000000000000645","volume":"28","author":"EP DeLoughery","year":"2017","unstructured":"DeLoughery EP, DeLoughery TG. Use of three procoagulants in improving bleeding outcomes in the warfarin patient with intracranial hemorrhage. Blood Coagul Fibrinolysis. 2017;28(8):612\u20136.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"10","key":"2588_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(18)30253-9","volume":"17","author":"R Al-Shahi Salman","year":"2018","unstructured":"Al-Shahi Salman R, Frantzias J, Lee RJ, et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol. 2018;17(10):885\u201394.","journal-title":"Lancet Neurol"},{"issue":"8","key":"2588_CR29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1212\/01.wnl.0000208408.98482.99","volume":"66","author":"SM Davis","year":"2006","unstructured":"Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66(8):1175\u201381.","journal-title":"Neurology"},{"key":"2588_CR30","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3389\/fneur.2020.00702","volume":"11","author":"Z Li","year":"2020","unstructured":"Li Z, You M, Long C, et al. Hematoma expansion in intracerebral hemorrhage: an update on prediction and treatment. Front Neurol. 2020;11:702.","journal-title":"Front Neurol"},{"issue":"1","key":"2588_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ana.25134","volume":"83","author":"ST Gerner","year":"2018","unstructured":"Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018;83(1):186\u201396.","journal-title":"Ann Neurol"},{"issue":"8","key":"2588_CR32","doi-asserted-by":"publisher","first-page":"947.e3","DOI":"10.1016\/j.ajem.2014.01.042","volume":"32","author":"JC Purrucker","year":"2014","unstructured":"Purrucker JC, Capper D, Behrens L, Veltkamp R. Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy. Am J Emerg Med. 2014;32(8):947.e3-947.e5.","journal-title":"Am J Emerg Med"},{"issue":"6","key":"2588_CR33","doi-asserted-by":"publisher","first-page":"e1202","DOI":"10.1097\/CCM.0000000000006656","volume":"53","author":"NG Panos","year":"2025","unstructured":"Panos NG, Jones GM, Cook AM, et al. Reversal of factor Xa inhibitor-related intracranial hemorrhage: a multicenter, retrospective, observational study comparing the efficacy and safety of andexanet and prothrombin complex concentrates. Crit Care Med. 2025;53(6):e1202\u201313.","journal-title":"Crit Care Med"},{"issue":"8","key":"2588_CR34","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jama.2015.0846","volume":"313","author":"JB Kuramatsu","year":"2015","unstructured":"Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824\u201336.","journal-title":"JAMA"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02588-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-026-02588-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-026-02588-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:54:35Z","timestamp":1784570075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-026-02588-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":34,"alternative-id":["2588"],"URL":"https:\/\/doi.org\/10.1007\/s12028-026-02588-y","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study has been performed according to ethical guidelines. No ethical approval was needed as this was a meta-analysis of previously published data.","order":2,"name":"Ethics","label":"Ethical Approval\/Informed Consent","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Artificial intelligence was not used in the preparation of this paper.","order":3,"name":"Ethics","label":"Artificial Intelligence","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"PROSPERO registration number: CRD42024556420.","order":4,"name":"Ethics","label":"Clinical Trial Registration","group":{"name":"EthicsHeading","label":"Ethics"}}]}}